Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Digital biofeedback for veteraner med PTSD-diagnose

1. oktober 2026 oppdatert av: NeuroBrave ltd.

Evaluering av effektiviteten til "Mental Gym®" biofeedback-basert intervensjon for krigsveteraner diagnostisert med PTSD: En randomisert kontrollert studie

This randomized controlled trial (RCT) will evaluate the effectiveness of a digital biofeedback-based intervention ("Mental Gym®") designed to reduce Posttraumatic Stress Disorder (PTSD) symptoms and improve mental health. The intervention combines daily HRV biofeedback exercises using a wearable device (Garmin watch), a dedicated mobile application, and weekly group guidance sessions. A delayed-intervention control group design will be used. To account for expected attrition and ensure a final sample of 60 participants, approximately 80 subjects will be recruited. Physiological and self-report data will be collected pre- and post-intervention, weekly during the intervention, and at follow-ups (3 months post-intervention). The study population consists of combat veterans diagnosed with PTSD.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

80

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Jerusalem, Israel
        • NeuroBrave LTD - Remote Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 50 år (Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Mann

Beskrivelse

Inclusion Criteria:

  • Sex: Male.
  • Age: 18 to 50 Years.
  • Diagnosis: Clinical diagnosis of Posttraumatic Stress Disorder (PTSD) with mild to moderate-severe symptom intensity.
  • Symptom Severity: A PCL-5 total score of up to 60 at screening.
  • Traumatic Event: PTSD diagnosis based on a traumatic event that occurred in the year 2000 or later.
  • Service Eligibility: Eligibility for Ministry of Defense (MOD) rehabilitation services.
  • Technical Proficiency: Ability to use a smartphone and a wearable device.

Exclusion Criteria:

  • High Symptom Severity: PTSD symptom severity exceeding the moderate-severe range (PCL-5 score > 60) or requiring more intensive clinical intervention.
  • Psychiatric Stability: Acute psychiatric instability, including active suicidal ideation or psychosis.
  • Medication: Current use of Olanzapine (Zyprexa) or Quetiapine (Seroquel).
  • Sleep Disturbances: Severe sleep impairment (score > 7 on the The Insomnia Severity Index).
  • Functional Impairment: Severe impairment in concentration or cognitive processing that precludes the use of digital biofeedback tools.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Mental Gym® Umiddelbar Intervensjon

The intervention is an 8-week hybrid program designed to reduce symptoms of PTSD and improve mental health. The program includes weekly online sessions (via Zoom) with a specialist psychologist experienced in biofeedback and trauma therapy. These sessions guide participants through the program, provide education on trauma and autonomic system and explain the biofeedback exercises. In addition to the weekly group sessions, participants engage in a dailyself-practice delivered through the NeuroBrave Sense mobile application, utilizing the provided wearable device ( Garmin watch) for real time biofeedback practices. Supplementary mental practice assignments are also delivered to participants via WhatsApp.

Ingen inngripen: Delayed Intervention (Waitlist Control plus Garmin Watch)

Participants in this arm will initially serve as a no-intervention control group for a period of 8 weeks, during which they will continue with their Treatment as Usual (TAU). Following this 8-week period, they will receive the full 'Mental Gym®' intervention, identical to the experimental group, including the mobile application, and weekly sessions.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in PTSD Symptom Severity (PCL-5 Total Score)
Tidsramme: Baseline (Week 0) and Post-Intervention (Week 8).

The primary outcome is the change in the total score of the Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5). The PCL-5 is a 20-item self-report measure; items are rated on a 0-4 point scale. Total score ranges from 0 to 80, where higher scores indicate greater symptom severity. PCL scores are expected to reduce in the intervention but not in the control groups.

Baseline (Week 0) and Post-Intervention (Week 8).

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Long term retention of Treatment Effects in the Intervention Group
Tidsramme: Baseline (Week 0), Post-Intervention (Week 8), 1.5-month Follow-up (Week 14), and 3-month Follow-up (Week 20)

To assess long term improvement trajectories and retention, we will combine all intervention arm participants and conduct longitudinal within subjects analysis on primary and secondary change measures at post intervention, as well as 1.5-month Follow-up (Week 14), and 3-month Follow-up (Week 20). This analysis will also be used to identify subpopulations within our sample for whom the treatment was more or less beneficial.

We expect the clinical improvement to remain significant through the follow up time points.

Baseline (Week 0), Post-Intervention (Week 8), 1.5-month Follow-up (Week 14), and 3-month Follow-up (Week 20)
Change in Autonomic Regulation (Resting HRV)
Tidsramme: Baseline (Week 0) and Post-Intervention (Week 8)

change in resting heart rate variability (HRV) will be used as a physiological marker of autonomic regulation. HRV will be derived from inter-beat interval data collected during 5 min resting conditions during the first and the last group sessions using a wearable device and summarised using standard time-domain metrics (e.g., RMSSD). Higher HRV values and lower heart rate (HR) reflect greater parasympathetic activity and improved autonomic regulation. Resting HRV scores are expected to increase and resting HR to decrease in the intervention but not in the control groups.

Baseline (Week 0) and Post-Intervention (Week 8)
Change in Generalized Anxiety Symptoms (GAD-7)
Tidsramme: Baseline (Week 0) and Post-Intervention (Week 8)

Generalized anxiety symptoms will be assessed using the Generalized Anxiety Disorder 7-item questionnaire (GAD-7), a validated self-report measure of anxiety severity. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptoms. Generalized anxiety symptoms are expected to reduce in the intervention but not in the control groups.

Baseline (Week 0) and Post-Intervention (Week 8)
Change in Depressive Symptoms (PHQ-9)
Tidsramme: Baseline (Week 0), Post-Intervention (Week 8)

Depressive symptoms will be measured using the Patient Health Questionnaire-9 (PHQ-9), a validated self-report instrument assessing the severity of depressive symptoms over the past two weeks. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. Depressive symptoms are expected to reduce in the intervention but not in the control groups

Baseline (Week 0), Post-Intervention (Week 8)
Change in Psychological Resilience (CD-RISC-10)
Tidsramme: Baseline (Week 0), Post-Intervention (Week 8)

Psychological resilience will be assessed using the 10-item Connor-Davidson Resilience Scale (CD-RISC-10), a validated self-report measure of perceived resilience and stress coping capacity. Total scores range from 0 to 40, with higher scores indicating greater resilience.Psychological resilience is expected to reduce in the intervention but not in the control groups.

Baseline (Week 0), Post-Intervention (Week 8)
Change in Sleep Quality (ISI)
Tidsramme: Baseline (Week 0), Post-Intervention (Week 8)

Sleep quality will be measured using the Insomnia Severity Index (ISI), a validated self-report questionnaire assessing subjective sleep quality. The total SQS score will be used, with higher scores indicating poorer sleep quality. Sleep quality is expected to reduce in the intervention but not in the control groups.

Baseline (Week 0), Post-Intervention (Week 8)

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Weekly Change in PTSD Symptom Severity (PCL-6)
Tidsramme: Baseline, and weekly through Week 8

The PTSD Checklist - 6-item version (PCL-6) is a validated self-report screening tool for Post-Traumatic Stress Disorder. It assesses symptoms such as intrusive thoughts, avoidance, and hyperarousal. Total scores range from 6 to 30, with higher scores indicate greater symptom severity. A decrease in scores over time represents clinical improvement.

Baseline, and weekly through Week 8
Weekly Change in Psychological Wellbeing (ORS)
Tidsramme: Baseline, and weekly through Week 8

The Outcome Rating Scale (ORS) is a 4-item visual analogue scale designed to measure change in three areas of client functioning: individual (personal well-being), interpersonal (family/close relationships), and social (work/school/friendships), as well as overall well-being. Total scores range from 0 to 40, with higher scores indicate better psychological wellbeing and functioning. An increase in scores over time represents improvement.

Baseline, and weekly through Week 8

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

15. september 2025

Primær fullføring (Faktiske)

14. september 2026

Studiet fullført (Faktiske)

14. september 2026

Datoer for studieregistrering

Først innsendt

5. mars 2026

Først innsendt som oppfylte QC-kriteriene

5. mars 2026

Først lagt ut (Faktiske)

10. mars 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

2. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

1. oktober 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • P_2025176

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere